

Contact information



Henrik Nagel, CEO



HNA@EYE-GO.COM



+45 96 98 93 39



www.EYE-GO.com

EYE-GO. Shaping the future of eye treatment.
2025 ESCRS iNovation Day

MistGo[®] is a user-friendly, superior alternative to conventional eye drops
Designed to help patients administer eye medication comfortably and precisely – in any head position!




”

It's delightfully easy to use.

You can't possibly do it wrong.


It solves all the hassles with eye drops.

Quotes from user study 2023



Micro-dosing: comparable pupil dilation and higher perceived comfort

Results from clinical test comparing a 6 µl & 30 µl dose of Tropicamide 1%¹ – in line with previous studies ²⁻⁴




1: 20 patients aged 18-42 tested at Copenhagen University Hospital 2023
2: Collins JF, Dartt DA, Dana R. Mist delivery of eye medication to the anterior segment. Am J Ophthalmol. 2007 Jul;144(1):137-9
3: Vocci, J et al. Reformulation and Drop Size of Apraclonidine Hydrochloride. Am J Ophthalmol. 1992 Feb; 113:154-160
4: Fiscella et al. Instillation Methods for Prostaglandin Meds. J Ocular Pharmacology and Therapeutics. 2006, 22(6):477-482

Study Results: MistGo[®] tested by 22 patients with glaucoma or high eye pressure


MistGo[®] offers a superior experience, empowering patients with a simple, comfortable, and precise solution - qualities vital for adherence and better outcomes.

Overwhelming preference


20/22 patients in the study preferred MistGo[®] over eye drops




Exceptional User-Friendliness



Superior Comfort



No Excess liquid



Company

- > Danish pre-revenue MedTech.
Backed by a strong investor group, including Topcon Healthcare, Inc.

Product

- > MistGo® - a micro-dosing, high-precision, ocular drug delivery system.
Mitigates the imperfections of current eye drop bottles.
For treatments with and without preservatives.

Market

- > Glaucoma and prescription DED eye medication (\$ multi-billion markets)

Business Model

- > Commercialization through pharma companies

Team

- > Management team with strong MedTech experience. 9 employees.

Traction

- > Functional, verified product. Studies completed. Launch planned for 2027.

EYE-GO A/S
Agern Allé 5
2970 Hørsholm
Denmark

Henrik Nagel, CEO
HNA@EYE-GO.com
+45 2199 0725
www.EYE-GO.com